Immunome, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Immunome, Inc. (IMNM) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $8.80 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-11
- Immunome, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $8.80M, a 64.56% increase year-over-year.
- Immunome, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $7.95M, a 39.45% increase year-over-year.
- Immunome, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $6.75M, a 37.92% increase year-over-year.
- Immunome, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $5.35M, a 65.70% increase year-over-year.
- Immunome, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $25.69M, a 63.13% increase from fiscal 2024.
- Immunome, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $15.75M, a 155.94% increase from fiscal 2023.
- Immunome, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $6.15M, a 15.40% increase from fiscal 2022.
- Immunome, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $5.33M, a 54.64% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $8.80M 10-Q · filed 2026-08-11 | $16.75M derived: sum of 2 quarters · filed 2026-08-11 | ||
| 2026-03-31 | $7.95M 10-Q · filed 2026-08-11 | |||
| 2025-12-31 | $25.69M 10-K · filed 2026-03-03 | |||
| 2025-09-30 | $6.75M 10-Q · filed 2025-11-06 | $12.09M derived: sum of 2 quarters · filed 2026-08-11 | $17.80M derived: sum of 3 quarters · filed 2026-08-11 | |
| 2025-06-30 | $5.35M 10-Q · filed 2026-08-11 | $11.05M derived: sum of 2 quarters · filed 2026-08-11 | ||
| 2025-03-31 | $5.70M 10-Q · filed 2026-08-11 | |||
| 2024-12-31 | $15.75M 10-K · filed 2026-03-03 | |||
| 2024-09-30 | $4.89M 10-Q · filed 2025-11-06 | $8.12M derived: sum of 2 quarters · filed 2025-11-06 | $10.28M derived: sum of 3 quarters · filed 2025-11-06 | $13.16M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $3.23M 10-Q · filed 2025-11-06 | $5.39M derived: sum of 2 quarters · filed 2025-11-06 | $8.27M derived: sum of 3 quarters · filed 2025-11-06 | $9.34M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-03-31 | $2.16M 10-Q · filed 2025-11-06 | $5.04M derived: sum of 2 quarters · filed 2025-11-06 | $6.11M derived: sum of 3 quarters · filed 2025-11-06 | $7.11M derived: sum of 4 quarters · filed 2025-11-06 |
| 2023-12-31 | $2.88M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | $3.96M derived: sum of 2 quarters · filed 2025-03-19 | $4.95M derived: sum of 3 quarters · filed 2025-03-19 | $6.15M 10-K · filed 2025-03-19 |
| 2023-09-30 | $1.07M 10-Q · filed 2024-11-13 | $2.07M derived: sum of 2 quarters · filed 2024-11-13 | $3.27M 10-Q · filed 2023-11-09 | $4.63M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $998.00K 10-Q · filed 2024-11-13 | $2.20M 10-Q · filed 2023-08-09 | $3.55M derived: sum of 3 quarters · filed 2024-11-13 | $4.89M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-03-31 | $1.20M 10-Q · filed 2024-11-13 | $2.56M derived: sum of 2 quarters · filed 2024-11-13 | $3.90M derived: sum of 3 quarters · filed 2024-11-13 | $5.22M derived: sum of 4 quarters · filed 2024-11-13 |
| 2022-12-31 | $1.35M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $2.69M derived: sum of 2 quarters · filed 2024-03-28 | $4.02M derived: sum of 3 quarters · filed 2024-03-28 | $5.33M 10-K · filed 2024-03-28 |
| 2022-09-30 | $1.34M 10-Q · filed 2023-11-09 | $2.67M derived: sum of 2 quarters · filed 2023-11-09 | $3.98M 10-Q · filed 2023-11-09 | $5.20M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $1.33M 10-Q · filed 2023-08-09 | $2.64M 10-Q · filed 2023-08-09 | $3.86M derived: sum of 3 quarters · filed 2023-08-09 | $5.01M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $1.31M 10-Q · filed 2023-05-05 | $2.53M derived: sum of 2 quarters · filed 2023-05-05 | $3.68M derived: sum of 3 quarters · filed 2023-05-05 | $4.43M derived: sum of 4 quarters · filed 2023-05-05 |
| 2021-12-31 | $1.22M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $2.37M derived: sum of 2 quarters · filed 2023-03-16 | $3.12M derived: sum of 3 quarters · filed 2023-03-16 | $3.45M 10-K · filed 2023-03-16 |
| 2021-09-30 | $1.16M 10-Q · filed 2022-11-14 | $1.90M derived: sum of 2 quarters · filed 2022-11-14 | $2.23M 10-Q · filed 2022-11-14 | $2.55M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $749.00K 10-Q · filed 2022-08-05 | $1.07M 10-Q · filed 2022-08-05 | $1.39M derived: sum of 3 quarters · filed 2022-08-05 | $1.51M derived: sum of 4 quarters · filed 2022-08-05 |
| 2021-03-31 | $325.00K 10-Q · filed 2022-05-12 | $644.00K derived: sum of 2 quarters · filed 2022-05-12 | $761.00K derived: sum of 3 quarters · filed 2022-05-12 | $800.00K derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $319.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $436.00K derived: sum of 2 quarters · filed 2022-03-28 | $475.00K derived: sum of 3 quarters · filed 2022-03-28 | $621.00K 10-K · filed 2022-03-28 |
| 2020-09-30 | $117.00K 10-Q · filed 2021-11-15 | $156.00K derived: sum of 2 quarters · filed 2021-11-15 | $302.00K 10-Q · filed 2021-11-15 | $305.00K derived: sum of 4 quarters · filed 2021-11-15 |
| 2020-06-30 | $39.00K 10-Q · filed 2021-08-16 | $185.00K 10-Q · filed 2021-08-16 | $188.00K derived: sum of 3 quarters · filed 2021-08-16 | $189.00K derived: sum of 4 quarters · filed 2021-08-16 |
| 2020-03-31 | $146.00K 10-Q · filed 2021-05-12 | $149.00K derived: sum of 2 quarters · filed 2021-05-12 | $150.00K derived: sum of 3 quarters · filed 2021-05-12 | |
| 2019-12-31 | $3.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $4.00K derived: sum of 2 quarters · filed 2021-03-25 | $14.00K 10-K · filed 2021-03-25 | |
| 2019-09-30 | $1.00K 10-Q · filed 2020-11-16 | $11.00K 10-Q · filed 2020-11-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |